AstraZeneca

AstraZeneca is a global pharmaceutical company focused on transforming the future of healthcare by unlocking the power of science for people, society, and the planet. The company is dedicated to creating genuinely innovative medicines and improving access to them for patients, healthcare systems, and societies globally. AstraZeneca's strategy involves three priorities: Science and Innovation, Growth and Therapy, and People and Sustainability. They are leading a revolution in oncology to redefine cancer care, transforming care for people with chronic diseases to deliver long-lasting immunity, and working to improve the lives of those affected by rare diseases through innovative medicines. The company is committed to operating sustainably, focusing on access to healthcare, environmental protection, and ethics and transparency.

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This news site is known for its high journalistic standards. It strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. It has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

5%

Examples:

  • AstraZeneca aims to double its revenue by 2030.
  • Li Auto reported earnings of $0.17 per share for the first quarter, lower than expected.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

  • Li Auto's Disappointing Q1 Earnings: 53% Sales Growth, Price Cuts, and Layoffs Ahead

    Li Auto's Disappointing Q1 Earnings: 53% Sales Growth, Price Cuts, and Layoffs Ahead

    Broke On: Monday, 20 May 2024 Li Auto reports lower-than-expected Q1 earnings and guides low for Q2, delivering 80,400 EVs in Q1 but missing sales targets. The company announces price cuts on all vehicles except the new L6 SUV and plans to lay off over 18% of its workforce. Meanwhile, AstraZeneca aims to double revenue by 2030 through growth in existing portfolios and launching new medicines, while decoupling carbon emissions from revenue growth since 2015.